SUV39H1 and diabetes mellitus: Therefore, SUV39H1 can be regarded as a treatment strategy for ischemia–reperfusion injury in diabetes mellitus.231 Weng et al.232 reported that IFN-γ treatment enhanced the expression of histone H3K9 trimethyltransferase SUV39H1 in endothelial cells and promoted the recruitment of SUV39H1 to eNOS promoter.